Taxus Cardium Pharmaceut... (PK) Stock Price

0.0002 (0.33%)
Best deals to access real time data!
Small Cap Pro
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Taxus Cardium Pharmaceuticals Group Inc (PK) CRXM OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0002 0.33% 0.0602 16:30:19
Close Price Low Price High Price Open Price Previous Close
0.0602 0.0572 0.0602 0.0585 0.06
Bid Price Ask Price Spread News
0.05 0.11 0.06 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
15 72,102 $ 0.059583 $ 4,296 381,720 0.0204 - 0.19
Last Trade Time Type Quantity Stock Price Currency
13:35:19 1,000 $ 0.0602 USD

Taxus Cardium Pharmaceut... (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 872.26k 14.49M - $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
25.83k $ - 0.00% - -

more financials information »

Taxus Cardium Pharmaceut... (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CRXM Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.06250.06390.05260.0600995137,625-0.0023-3.68%
1 Month0.0640.07310.04950.0631262303,609-0.0038-5.94%
3 Months0.07630.10790.04950.077456380,884-0.0161-21.1%
6 Months0.120090.15930.02040.0779023295,427-0.05989-49.87%
1 Year0.11050.190.02040.0789802154,599-0.0503-45.52%
3 Years0.130650.190.02040.082039762,679-0.07045-53.92%
5 Years0.16020.390.01050.099084144,383-0.10-62.42%

Taxus Cardium Pharmaceut... (PK) Description

Cardium Therapeutics is a health sciences and regenerative medicine company focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs that have definable pathways to commercialization, partnering and other economic monetizations. Cardium's current medical opportunities portfolio, which is focused on health sciences and regenerative medicine, includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium Health Sciences healthy lifestyle product platform. The Company's lead commercial product Excellagen(R) topical gel for wound care management, has recently received FDA clearance for marketing and sale in the United States. Cardium's lead clinical development product candidate Generx(R) is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio.

Your Recent History
Taxus Card..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.